Skip to content

Phio Pharmaceuticals Corp

PHIO

CIK 0001533040

← back to feed
Revenue (TTM)
$0
−100.0% YoY Q1 May 2026
Net Income (TTM)
−$10.33M
−21.7% YoY Q1 May 2026
EPS Diluted (TTM)
−$6.02
+80.6% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$10M
Q1 May 2026
Cash
$17.03M
Q1 May 2026
Total Debt
$0
Q1 May 2026
Shares Outstanding
11.62M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings